Rockville, MD - February 18, 2011 - Accelovance, a privately held clinical research organization reported its sixth year of continued revenue growth after closing out a successful 2010. The year included an award of two Phase III rescue studies; several contracts with biotech companies initiating Phase I and Phase II clinical programs; and new relationships with government-funded Sponsors. Accelovance also gained continued industry recognition for its best-in-class services with a second, consecutive "BEST CRO" ViE Award.
"The past 12 months have been remarkable, with 30% top line growth over last year. We are proud of the efficiencies our enhanced study management has to offer," commented Steve Trevisan, President and CEO of Accelovance. "Revenue growth and industry awards support our ability to deliver clinical solutions through a flexible offering of a CRO, Clinical Sites, Patient Recruitment and Clinical Call Center." In 2010, the Washington Business Journal added Accelovance to its annual list of 50 Washington-area Fastest Growing Companies.
New programs will capitalize on Accelovance's integrated service approach; CRO, sites and recruitment solutions within our core market of vaccines, immunology and primary care conditions. The CRO division will continue to focus on the business needs of biotech and small/mid pharma with expanded areas of expertise in oncology, cardiovascular and cell/gene therapy. An increased interest in Accelovance's Clinical Call Center to support retention, compliance, recruitment efforts and observational studies for Large Pharma indicates additional growth opportunities over the next 12-18 months.
"A flexible, innovative offering that can be utilized by Sponsors big and small alike gives Accelovance a diverse client base that will support overall corporate growth," commented Trevisan. Accelovance also had a 15% increase in employees to support new programs and expanded therapeutic expertise. Similar hiring activity is anticipated for 2011.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The Company tailors its offering of a full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets Sponsors' needs. Accelovance's ownership and operation of six (6) research-dedicated clinical sites provides operational insight to study conduct and patient recruitment that other CROs never acquire. Additionally, Accelovance has a wholly owned subsidiary providing regulatory consulting and CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.
For more information, visit the company's website at http://www.accelovance.com.